Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, has shown 100% efficacy in preventing HIV in women at high risk of infection during an interim analysis of the phase 3 PURPOSE 1 trial. The results were so promising that Gilead Sciences stopped the trial’s blinded phase and offered open-label lenacapavir to all participants. The drug is being compared to Descovy and Truvada, with lenacapavir proving more effective. Participants found the injection to be discreet and convenient, increasing adherence. Concerns remain about accessibility, especially in low- and middle-income countries. Additional trials are ongoing, with regulatory filings for lenacapavir as a PREP option expected if results continue to be positive.
Source link
No HIV Infections After Twice-a-Year PREP
